<SEC-DOCUMENT>0000200406-13-000096.txt : 20130820
<SEC-HEADER>0000200406-13-000096.hdr.sgml : 20130820
<ACCEPTANCE-DATETIME>20130820172057
ACCESSION NUMBER:		0000200406-13-000096
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130819
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130820
DATE AS OF CHANGE:		20130820

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JOHNSON & JOHNSON
		CENTRAL INDEX KEY:			0000200406
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				221024240
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			1212

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03215
		FILM NUMBER:		131051402

	BUSINESS ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
		BUSINESS PHONE:		732-524-2455

	MAIL ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a20130819aragon.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using WebFilings 1 -->
		<!-- Copyright 2008-2013 WebFilings LLC. All Rights Reserved -->
		<title>2013 0819 Form 8-K - Aragon</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s5AEABFD0774AFFAB121188B2FD3A2291"></a><div></div><br><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WASHINGTON, DC 20549</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 8-K</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Pursuant to Section 13 or 15(d) of the</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Date of report (Date of earliest event reported):&#160;&#160;August 19, 2013</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;"><img src="form8ktemplateimage1.gif" style="height:46px;width:181px;"></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="31%"></td><td width="38%"></td><td width="31%"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New Jersey</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I-3215</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22-1024240</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or Other Jurisdiction of Incorporation)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission File Number)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(IRS Employer Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">One Johnson &amp; Johnson Plaza, New Brunswick, New Jersey&#160;&#160;08933</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of Principal Executive Offices) (Zip Code)</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Registrant&#8217;s telephone number, including area code:&#160;&#160;732-524-0400</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><a name="s5AEABFD0774AFFAB121188B2FD3A2291"></a><div></div><br><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8.01  Other Events. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 19, 2013, the Registrant announced that it has successfully completed the previously disclosed acquisition of Aragon Pharmaceuticals, Inc., a privately-held pharmaceutical discovery and development company focused on drugs to treat hormonally-driven cancers.  A current report on Form 8-K announcing the definitive agreement to acquire Aragon Pharmaceuticals, Inc. was filed on June 20, 2013.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The related press release dated August 19, 2013 is attached as Exhibit 99.1 to this Report.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01  Financial Statements and Exhibits.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d) Exhibits.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibit No.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Description</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Johnson &amp; Johnson press release dated August 19, 2013.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="50%"></td><td width="5%"></td><td width="33%"></td><td width="12%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Johnson &amp; Johnson</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;(Registrant)</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:  August 20, 2013</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/S/  DOUGLAS K. CHIA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Douglas K. Chia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Secretary</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a20130819aragonex99.htm
<DESCRIPTION>EXHIBIT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using WebFilings 1 -->
		<!-- Copyright 2008-2013 WebFilings LLC. All Rights Reserved -->
		<title>2013 0819 Form 8-K Aragon Ex. 99</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sf0523bf580db4d6bab55e577d2d517f0"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:right;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit 99.1</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="34%"></td><td width="33%"></td><td width="33%"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Contacts:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Media:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Al Wasilewski</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Lisa Varga</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Johnson &amp; Johnson</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">732 524-1130 (o)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">908 218-7316 (o)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">732 447-5918 (c)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">908 670-0263 (c)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Investors:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Lesley Fishman</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">732 524-3922</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></td></tr></table></div></div><div style="line-height:180%;padding-bottom:13px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">FOR IMMEDIATE RELEASE</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">JOHNSON &amp; JOHNSON COMPLETES ACQUISITION OF ARAGON PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Late-Stage Prostate Cancer Treatment Strengthens Oncology Pipeline</font></div><div style="line-height:174%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">New Brunswick, NJ (August 19, 2013) --</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:11pt;">Johnson &amp; Johnson (NYSE: JNJ) today announced it has successfully </font><font style="font-family:inherit;font-size:11pt;">completed its acquisition</font><font style="font-family:inherit;font-size:11pt;">&#32;of Aragon Pharmaceuticals, Inc., a privately-held pharmaceutical discovery and development company focused on drugs to treat hormonally-driven cancers.  Development of compounds from Aragon's androgen receptor antagonist program, including its lead androgen receptor signaling inhibitor, ARN-509, will be managed by Janssen Research &amp; Development, LLC.</font></div><div style="line-height:174%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;The acquisition strengthens our prostate cancer pipeline with a second-generation, potentially best-in-class compound,&#8221; said Peter F. Lebowitz, M.D., Ph.D., Global Therapeutic Area Head, Oncology. &#8220;It builds on our existing leadership position with ZYTIGA&#174; (abiraterone acetate), and, if approved, we are hopeful ARN-509 will allow us to meet the needs of an even broader range of prostate cancer patients.&#8221;</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div><div style="line-height:174%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">About Johnson &amp; Johnson</font></div><div style="line-height:174%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Caring for the world, one person at a time&#8230;inspires and unites the people of Johnson &amp; Johnson. We embrace research and science-bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 128,000 employees at more than 275 Johnson &amp; Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.</font></div><div style="line-height:174%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">About Janssen Research &amp; Development, LLC</font></div><div style="line-height:174%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Janssen Research &amp; Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, is headquartered in Raritan, N.J. and has affiliated facilities in Europe, the United States and Asia. Janssen Research &amp; Development is leveraging a combination of internal and external innovation to discover and develop novel medicines and solutions in five distinct therapeutic areas:  Neuroscience, Oncology, Immunology, Infectious Diseases and Vaccines, and Cardiovascular and Metabolism. For more information about Janssen Research &amp; Development, LLC, visit</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;">www.janssenrnd.com</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sf0523bf580db4d6bab55e577d2d517f0"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research &amp; Development, LLC and/or Johnson &amp; Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; and increased scrutiny of the health care industry by government agencies. In addition, there will be risks and uncertainties related to the ability of Janssen Research &amp; Development, LLC and/or Johnson &amp; Johnson to successfully integrate the business of Aragon Pharmaceuticals, Inc. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson &amp; Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2012. Copies of this Form 10-K, as well as subsequent filings, are available online at </font><font style="font-family:Arial;font-size:10pt;color:#0000ff;font-style:italic;text-decoration:underline;">www.sec.gov</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">, </font><font style="font-family:Arial;font-size:10pt;color:#0000ff;font-style:italic;text-decoration:underline;">www.jnj.com</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#32;or on request from Johnson &amp; Johnson. None of the Janssen Pharmaceutical Companies or Johnson &amp; Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">#     #     #</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>form8ktemplateimage1.gif
<TEXT>
begin 644 form8ktemplateimage1.gif
M1TE&.#EAM0`O`/<``)H<*8\S/HT\.YDC*9@J-9@X)I8U.ZD:'K<-#K@,&;@5
M&ZL:)ZD<-+H:)[@9,JDB'ZDE**8H-J,T/*<Z-:\R-:XT/*X\,:L\.;0D([0B
M+;,K*KDC)+PC+;PN++<G-K<S.I@Y2*4L0:@X1[HM1;@W1KPX5;-$-H]#38]/
M4)5"0))#2)E`1IY!5)153)=26J9%2*E+4Z=26K=#2+=&5;%23K=46*148;M+
M8;E99ZIE9ZQP<+=D;+YB:[]K:+IR:+1R<\H*&LH5&M$.%M0/&MH(%=T.'=$6
M#]45&\H*(L,2),83*\0;),(;+,L3(\H3+,H:(\H;*\D;,]@))M4)-M87)M,8
M-L,B*L(I+,PC(\HC*\4G-\DR)\DS.],C*M<E-],R-^42&>85)N85-_,<,>,C
M+>8I.NHQ+O$A+_\[/,4;0\8I1<<V1L([5-@G1-DM4-HY1]8Q4-,_5=P^5^,J
M1.@W2.`\5_\S3/<Y5\%$2\=+4\%,6\M!4,Q&6LI,5,Q)6LE56]E$2-A+5]U<
M7<I)8<979-A(8M5:9]%<=]M4=-M><-!E7<IG:,MG=L-T<\)U?,%\?,MQ<,]R
M?,]Z=\A\?M9E:-9H==9U>.9`0.1%6>I36OQ#2?5,7_A/5N=9:>-><O)+:?U7
M:?Y7<^1I:.=H=^9S<.1S>^%_?/)B;/IH=O!Q:_]S=?YT?+1]@,MX@\-]E=5I
M@-MWA.%OB.=VA?UD@/UM@O]OCOUWAOU\D\&`?J^2CLB'A\R4E\N;F=:"B-N,
ME-J7F-JCFM6DIM2PLN>&B>N'E.23AN>6F/B(B_V(EOV2BON6F.6;I?J)H?V9
MI?^=LNJADOJKGNFEI^:JMNBTJOBFJ?ZHM/RTK/ZVN?^LQ/VXQ?^\TNK!N_[#
MNO;&Q/_#P__#RO_*QO[*R__)U?_0Q__4S?[8V?_*X?_;Y?_>\/_CV__RWNCN
M[.SWZ^O\]_/K[/_CY/_DZ_[KY/[KZ__D\__E^O[L\__L^OWTZ_3V]/3U^O3]
M]/3^_?[S\_[T^_W[]/[^_BP`````M0`O`$<(_P#_"1Q(\-^^@P43*D1H\.`^
M@0P52IQ(L:+%BA$;0GQXL:/'CP7Q"?3WCV1)C"7]J03)LN7$?OU.CA08$Z)"
ME?[N<:SILB?(?N$\.#`'[UH60/(6"N27$QZ)!K:0Z:GWCY]`=@=KFBRI[U_,
MF/O:\:QJD*!*JPV[BOR7;VF[@C'C67(PRQZ].U&HW;NWE>Q`?^F>9:$B3L2U
MF.W:<91)L"M!M&];CI6XN.2]N;3DE0,2ALNU>,F.'"DG4%ZZ`M/NO<O0!%6$
M;.^>@A)G@%LZ3E3HH.KU;I4"#N*0$4IG38H86^?>R:B"R9Z]?_>0K;G'#YL#
M)[8BB`/W((LM>?SD\?^(\ND;+"U>UI0KETU*FW/U.CW!0$D>O"Y!CJ7+J:X8
MC7?Q'$/%&*@P4@\U01#6B@[Q7'-`%JA\$`XX&"R!BC@@1)..)D<T`-\U3CCA
M#4GVG"/"+_*\T\<1:&!R"SR5!+%%//S4N%!E_O`32R7WQ),-`=)095)E/A5I
MI%<8AG./>#/,4Q-:1T8I957U,#7EE5+6R%=?6'8)4D9>AAFE0QN):29E'*E4
M3R\&7"-.!.$L51"13FEQ#@B^5'EFD:J)4,DYK3@"3U(V#:15=!XHTPP(>NY9
M9'P-+&*?+**5PX\]VO#AP2+7>("*!\W,,T\U40!Q3#SQ=-*`![`(!,\Q"EC_
M@4.5U3@0!03R^"./.`#,4,Y>U9``A0+0^&!"*A^(D\T,'BQ``3?\S*-&%5HT
M0U5*CNV58S8>/'"-/.=0084I\=@S#S(1&"".''5T(L,Y\)CSB115O'-/-FH$
M<<4[_=23#1RW7K.D'PTTH$Q2\BP2P37JW'-.(<,J`@X$J%B@3#FRC."`%8+<
M4P\S:52Q!CR%_I503CG6,\@GMC10B9/]R!..#!FL44HY7_7S`PPX>[7+"\I<
MRT\U*4QC53_?R*"'."6]$P,(O3#%3D[#D!#!#,90)U`Y*.0`#TSW_'+U.57A
M!-X]P`2#5HW6<%%-!A"(\U4YQT10`2'4H.4O"]58_YG.'S*$8Q4_Y\3`"#HP
MR?/("\U\/<\R(.``SUGW@$-(!'Z2HPX[7BTC0C9,^7,.#"+XPI1C%?FS#`&_
MIJ/N9(Z>Z4]LF=T#BR5\C>0/ZK'W[OOO)P,O_/#$HU2\F&$1>1&9QW?$D?()
M*<]\\Q8YI!(\XO!P@C!04J1K-3M$8R/U-U;%3SW+/#W/13F50PPC[WA%_D#0
M\R..`VNHHTX@6A!*_V(P.9\C/%4.`D0C=V!J7HX\X8%KI,,9#CC@[BA3$G%$
MH0KD,,8+_#<_W0VD'J6`P"+@48]A4"$+\1-(/7*RE[TL!1X4:``=""$/>6AK
M(-'*U4!0M15^W#!'50'/.__``Z5ZS*.(5>+'DQCCCX><8P`9`!T\&K"$K%GE
M+#;4&E/B@0SCD$`OJ@'/0-Y1HZ.QT'_]@`<_PE(5Y]3#B/78DA++2!(EOE$C
M%N%',Z)`@G/<`T%':`8U"("*(E!!'OW(!B,T`($:4$,<6F@`,LHA`V5X00J@
MF$<]:G`,301A#>=`AB=0`04(G$,>G8J"%.[@@5*<8Q1,6$4][&$,&;Q!"]Z0
M!P0Y\,@1D$J2H?-'/08%CV8,`!;O>,<%,*",\ZTA"&\0QR`*,8<$4.,=YX"%
M#"Y`@&-<0T!->$<T<-",(P0A'4/S90.TH`QQ5(`:5J#"*H98B#(480B@(($X
MM"'_!2C\2AR'B(,'+'&.<P#B"&8H1R5D08LP=(&,'6%A-B(PBF9(@0JC$"(7
M@.`%6V@#&9MZXSD\@`0FG,-<'VB"%V"0*WD(8@E1^(X\5I$`)>P!1=58`S.T
M4`D;4F,)5*C6-40!`67$XQ[7:``0M)".>Y#C`&&X@QJ88<-J,"($`/#`!_+0
MC&[<(QPU($$V[$`%")3#.;:(0A+>4(UF=,(#XG@C,:8@!EF0D!I'"(,#JI&3
M;$1!"6H`4#@R`(0YC$`<Y0":%@9`CAY]@0P-0$4VFF$%I/1C'GRXZ##D`4(@
MC"$4(G@'E[B$PWJT0A?IN`8$7D$/JQPD)TH42&2\TH^<_]#6'FUQ53]<6S8Q
MCD1K\CM)/^@Q%IB0I2M,42)8%K,5?\#$'"DHQSLN)SB$Q(PI8'D+"R<H/Y.@
MA2?M8"%!.+@3X\:DCJ49B#M@`CN*V$\$XMA+,TKPG`Y&21Z5,`1?W@&#O)V7
MM/9MB3_N-P4WA!;``6:)KCK1AB@P(&LD@5Z"C3?AWJVDPE*2,(:/=.&$Z(-W
M&_Y2B(FGX0`G<,1G@EZ)$WQB%!^)>2UV\?)6/)$8RY@@"61>>SO($.K4J!X<
MK(B/DX)@ZNTCMSXLXS^N95SEP?9L:YDP0QY2(V/,H!J54-M%]$@"600@&[NM
M\-3N48X81"(;(G#21IP\NQGPP?\0+K!*E"N<(W1=$QD,(%N'2Z;$I(+B'#7(
MDVMI##S"B6`&!7V!+K2VW)/%8PU1^$8STER6^2DO9H2(PBWBD0X.<.$>(UG,
M3J@4@PRLHAH2*,=6;%QH;SA`#35$15[XPCG8/02I54!".1HQB6L%6"4<J8<R
M(/"N>33C"5_0R=H&`FKHJ`8`6K#%&AHW1U`_!"87UI9(C*N/:R^E)CSA2\RN
M\EOO&NHQ\;@`!YIAKC8X02\=+NY>BI&$,@C'MUD9R='ZX0Z<R&DCZZ`)3283
M;IH0"L0F^R!1(<%965#A"4F!R>-:8(U%U*!O(LT`%1KPC7240Q("B-,^PE,*
M"02C-,C_$`$N",4/5FRC1SER7PU:,(X>]$!P_<CF#!S!67LLZP4].YD_WO*-
M#T#@&H1;PA.,H=QZE",'/_!&#'1A*7[``QEBD((L4D0-&5#"1D,3`0S(V(\R
M`_UHXK#!"O71+RROH!FPJ`$PFHI*'+S`&BJ91RM"T(Q&5X0?J&A`#6JHC"`<
MX5OBF$$3J'"-<HR@%IOP`#)NH(8D4,$6Q-&"N%!1CWZ(XP!DH$*3X#$#+U"!
M`[^2AR&TL-==$\(65"A#.:@Q`64`8@TBN`4RM,!,>!!C#E)P`C*NZ&]^4,,'
MX=`,`#!PC7J<`PI4$`4VS],`0YPC%&X`*24J00(M2&$.\2A'_Z;#@(!?U:,2
M59`"!XQJC#<@H374R48#G@`(XDC@%F2U!CGP@`I5:``/?N`,;R`$E[`>)9!^
M7N`DN14]9E$.0I$-\F`-05`$F+`PQP`&9!`__5(.)@`-\7`.&;`$JW`,E%`.
M'T`%J'`.&E0.FD`%@/`-8J4*#:`!ZT$(R-!%4H`<[_`"4&$/,%%,'K`DU>`!
M#=`,J$`+WX`!&W`,6Q(.E2`".=`+V;`&?W`.Z4`*#7`*LQ0(*L4%B2`.98`%
M1@5DZ3`,,E`.`7($9%`.*B`.S1`$02!=+U`-UX`!DH0*J^`-&Q`$J``/U"!6
M9Q`&56`.QE8%2<`7=G$.;&`,*8('1O^`!M4@`N5`"4>`!3128V9!9B.@'NE`
M!D6`"O;"#0F"#/`P#Q%8`$T%#QK7!'9U#A60!:`0",1P#^F0">+B`>60#K:0
M!0TP4=E`25Z`!(8P1)3`42=50Y1`"4*H>5JP6>4``4&`#.+@`O+@"PX`!]5P
M#K8`!1XP"HLP`U$0!<0`#[:P!!#05.>`"53P`4-$BR\`">GP#LH@!5*@3_70
M#%1`!,X``DT5#AR0!%IP#._PC$^`"J/`"/)0#%_0!0VD&5#0!,-`(_50#1'P
M#?;1!T-P!*`$(UV`!>G`"[G`/OH@A!'0!F4`!91`%4/3`%[@!%'@`3+P#3XX
M#P,0;>92#S/_4##?4"/R0`D+T$?A<0P.H`5ZP!?*L`:ND3<Y00FQH@4'($(T
M<@_>,`!<@`RY$@\0X`1SP`;HX$-+`@\%I0P\D"M\40YKT`1B4`40(),EX@=,
M\)+-(@MOU`_+D`9J(`XU0@T*@%'GD!/AP`#1)D01$`4-@`WS``\&@`P?,'A[
M<0T*L$X-D`$=@'27<@-1H`6J)@_#$(QJT`Q68A8W$7,S$!P>@`,^&!-+\@[P
M$#^+043?!0_/816<Y5M5,41Z`AY)Q&SW4(J=!Q:T%5NU%1Z^Y@]3$TQPL0BB
M4`Y6\PU4\1##-$16H1A>X4--I`_AH4.#(P_.<2C\`A/.X8-^L63SYH`.<52=
MYZ-&,O%&068RRN-\('!4$P4+1V00B3%;]+D5N?,5E28_UG-A/#$]E49P,=%M
M,U$F".<5]N`*NA`/\(`#$="7-39R.$&@<Y(2:[8/N5.@`G&@.%006[%C]),0
M\C`#S;`7U!`"I!%<-S81>C0#3`$/AM-Y,T%H+N8/UR`"?G0/E8`,(+JB?\$/
M;&`+>R$.K&,2>^:C"G$/T1`"V%`.C]`*Y]"C2*HK:X`)Y_`-ZI*A2&H1.8((
M:5`(VM`]6WH30\,`:H`,*Q1A8QJB%,%J:VH0^M`.'/JF=%JG=OIK$U%D&Q80
"`#L_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
